EP0190367B1 - Benzo-a,d,h-b,d-cinnolin-verbindungen, deren herstellung und arzneimittel die diese enthalten - Google Patents

Benzo-a,d,h-b,d-cinnolin-verbindungen, deren herstellung und arzneimittel die diese enthalten Download PDF

Info

Publication number
EP0190367B1
EP0190367B1 EP85904155A EP85904155A EP0190367B1 EP 0190367 B1 EP0190367 B1 EP 0190367B1 EP 85904155 A EP85904155 A EP 85904155A EP 85904155 A EP85904155 A EP 85904155A EP 0190367 B1 EP0190367 B1 EP 0190367B1
Authority
EP
European Patent Office
Prior art keywords
compound
cinnolin
tetrahydrobenzo
formula
carbon atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP85904155A
Other languages
English (en)
French (fr)
Other versions
EP0190367A4 (de
EP0190367A1 (de
Inventor
Tetsuya Tahara
Minoru Kawakami
Shuzo Takehara
Masamitsu Sakamori
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Welfide Corp
Original Assignee
Welfide Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Welfide Corp filed Critical Welfide Corp
Priority to AT85904155T priority Critical patent/ATE49595T1/de
Publication of EP0190367A1 publication Critical patent/EP0190367A1/de
Publication of EP0190367A4 publication Critical patent/EP0190367A4/de
Application granted granted Critical
Publication of EP0190367B1 publication Critical patent/EP0190367B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/36—Benzo-cinnolines

Definitions

  • the present invention relates to novel and pharmaceutically useful benzo[h]cinnoline compounds, methods of preparing said compounds and pharmaceutical compositions containing said compounds.
  • European Patent Application No. 124314 discloses 3H-indeno-pyridazin-3-one derivatives with cardiotonic and antihypertensive activities.
  • European Patent Application No. 0 169 443 A discloses hypotensive, vasodilating, anti-aggregative, antithrombotic and cytoprotective benzo[h]cinnoline compounds represented by, for example, 8-amino-4,4a,5,6-tetrahydro-2H-benzo[h]cinnolin-3-one.
  • the present inventors have made intensive studies in order to develop useful drugs. As a result of such investigations, the present inventors have found that novel benzo[h]cinnoline compounds have potent affinity for benzodiazepine receptor and antianxiety activity.
  • the present invention relates to benzo[h]cinnoline compounds represented by the formula:
  • each of X and Y is hydrogen, halogen (e.g. fluorine, chlorine or bromine), trifluoromethyl, hydroxy, alkyl having 1 to 4 carbon atoms (e.g. methyl, ethyl, propyl, isopropyl, butyl or isobutyl), alkoxy having 1 to 4 carbon atoms (e.g. methoxy, ethoxy, propoxy or butoxy), nitro, cyano, alkanoyl having 2 to 4 carbon atoms (e.g.
  • Ar is pyridyl, pyridyl substituted by a halogen, or phenyl which may be optionally substituted by at least one substituent selected from the group consisting of halogen (e.g. fluorine, chlorine or bromine), trifluoromethyl, hydroxy, alkyl having 1 to 4 carbon atoms (e.g. methyl, ethyl, propyl, isoproyl, butyl or isobutyl), alkoxy having 1 to 4 carbon atoms (e.g. methoxy, ethoxy, propoxy or butoxy), amino, alkanoylamino having 2 to 4 carbon atoms (e.g. acetamido, propionamido or butyrylamido), nitro and cyano; and the bond position indicated by dotted line is single bond or double bond.
  • halogen e.g. fluorine, chlorine or bromine
  • trifluoromethyl hydroxy
  • the compounds of formula (I) of the present invention can be, for example, prepared by the following Methods 1, 2 and 3.
  • the compound of the formula (I) can be prepared by reacting a compound of the formula: wherein R is hydrogen or alkyl having 1 to 4 carbon atoms (e.g. methyl, ethyl, propyl, isopropyl, butyl or isobutyl) and other symbols are as defined above, with a hydrazine compound of the formula: wherein Ar is as defined above, or acid addition salt thereof (e.g. hydrochloric acid salt), and then subjecting the thus obtained compound of the formula: wherein each symbol is as defined above, to a ring closure reaction.
  • R is hydrogen or alkyl having 1 to 4 carbon atoms
  • Ar is as defined above
  • acid addition salt thereof e.g. hydrochloric acid salt
  • the reaction of the compound of the formula (II) with the compound of formula (III) is carried out by refluxing under heating for 5 to 20 hours in a suitable solvent, for example, in an alcoholic solvent such as methanol, ethanol or propanol.
  • a suitable solvent for example, in an alcoholic solvent such as methanol, ethanol or propanol.
  • an acid scavenger e.g. sodium acetate, potassium acetate, sodium hydrogencarbonate, sodium carbonate or potassium carbonate.
  • the ring closure reaction of the obtained compound of formula (IV) is carried out by refluxing under heating for 5 to 10 hours in acetic acid.
  • the compound of the formula (I), wherein the bond position indicated by dotted line is double bond can be synthesized by adding bromine in acetic acid dropwise to the compound wherein the bond position indicated by dotted line is single bond [Journal of Medicinal Chemistry (J. Med. Chem.), Vol. 14, p. 262 (1971)], and preferably by adding 1 to 1.5 times moles of bromine dropwise to the compound of the formula: wherein each symbol is as defined above, at 20-60 0 C in acetic acid.
  • the compound of the formula (I) wherein the bond position indicated by the dotted line is a double bond can also be prepared by reacting the compound wherein the bond position indicated by a dotted line is a single bond with sodium m-nitrobenzenesulfonate (Bachmann Method, British Patent No. 1 ' 168 291).
  • Such methods include, for example, reduction of a nitro group to an amino group; acylation of an amino group with a lower alkanoic acid; and conversion of an amino group into a cyano group (e.g. Sandmeyer reaction or Gattermann reaction).
  • a displacement ability for benzodiazepine receptor is shown as follows:
  • a specific binding for benzodiazepine receptor was determined according to the methods described in European Journal of Pharmacology, vol. 51, p. 129 (1978) and Life Science, vol. 20, p. 1201 (1977).
  • the crude synaptosomal membranes were prepared from the cerebral cortex of 9 to 10 week- old male Wistar rats and were suspended in Tris-HCI buffer (pH 7.4).
  • Tris-HCI buffer pH 7.4
  • Various concentrations of test compounds and tritiated diazepam final concentration: 2 nM were incubated at 4°C for 20 minutes. Then the suspension was filtered through Whatman G GF/B glass fiber filters. Radioactivity of tritiated diazepam on the filters was measured by liquid scintillation spectrometry. Specific binding was defined as the difference in the amount of radioactivity bound in the absence and presence of 1.0 x 10- 6 M unlabeled diazepam.
  • the affinity of the compounds of the present invention is evaluated as an ability to displace tritiated diazepam from the binding site, and is represented as Ki value.
  • Ki value The results are summarized in the Table 1.
  • the compound of Example 13 was orally or intraperitoneally administered to mice. All mice survived at the oral dose of,1000 mg/kg and at the intraperitoneal dose of 250 mg/kg.
  • the compounds of the present invention when used as drugs, can be administered in the form of pharmaceutical composition such as tablets, capsules, granules, powder, syrup, injectable solutions, suppositories or the like by mixing a therapeutically effective amount of the compound of the present invention with pharmaceutically acceptable additives (excipient, carrier, diluent and so on).
  • pharmaceutically acceptable additives excipient, carrier, diluent and so on.
  • the daily dose for example, in an oral administration for human adults usually ranges from 5 mg to 500 mg in a single or multiple doses.
  • the tablets containing 20 mg of the compound (I) of the present invention can be prepared by the following composition.
  • Compound (I) is crushed with an atomizer to make a fine powder having an average particle size below 10 ⁇ .
  • the fine powder of Compound (I), lactose, corn starch and crystalline cellulose are mixed well in a kneader and then kneaded with a binder prepared by polyvinyl pyrrolidone.
  • the wet mass is passed through a 200 mesh sieve and then dried in an oven at 50°C.
  • the dry granule containing 3-4% of water content is forced through a 24 mesh sieve.
  • Talc and magnesium stearate are mixed and compressed into tablets by using a rotatory tableting machine with a flat punch of 8 mm diameter.
  • a mixture of 12 g of 7-chioro-1,2,3,4-tetrahydro-1-oxo-2-naphthaieneacetic aciod and 8.1 g of phenylhydrazine in 150 ml of ethanol is refluxed under heating for 14 hours. Then the ethanol is distilled off under reduced pressure, 100 ml of acetic acid is added to the residue and the mixture is refluxed under heating for 7 hours. After the acetic acid is distilled off, the residue is extracted with chloroform. The extract is washed with water, dried over magnesium sulfate anhydride and then the chloroform is distilled off to give crystals.
  • the precipitated crystals are collected by filtration and recrystallized from alcohol to give 11.1 g of 9-chloro-2-phenyl-4,4a,5,6-tetrahydrobenzo[h]cinnolin-3(2H)-one as colorless prisms, melting at 120-122 0 C.
  • a mixture of 5 g of 1,2,3,4-tetrahydro-1-oxo-2-naphthy)ideneacetic acid and 3 g of phenylhydrazine in 100 ml of ethanol is refluxed for 10 hours.
  • the precipitated crystals are collected by filtration, washed with ethanol and dissolved in 50 ml of acetic acid.
  • the solution is refluxed under heating for 8 hours and the acetic acid is distilled off.
  • the residue is extracted with ethyl acetate and the extract is washed with an aqueous sodium hydrogencarbonate solution. After drying over magnesium sulfate anhydride, the solvent is distilled off and to the residue is added ethanol.
  • 2-(4-Aminophenyl)-9-chloro-4,4a,5,6-tetrahydrobenzo[h]cinnolin-3(2H)-one is added to the mixture of water and concentrated hydrochloric acid which is cooled on an ice bath and then an aqueous solution of sodium nitrite is added dropwise. The mixture is stirred under ice-cooling for 30 minutes and then neutralized with sodium carbonate. The solution is added dropwise with stirring to a solution of cuprous cyanide and potassium cyanide which is previously prepared. The mixture is stirred under ice-cooling for 30 minutes and allowed to stand overnight at room temperature. The precipitated crystals are collected by filtration to give 9-chloro-2-(4-cyanophenyl)-4,4a,5,6-tetrahydrobenzo[h]cinnolin-3(2H)-one.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (10)

1. Benzo[h]cinnolinverbindung der Formel
Figure imgb0014
worin X und Y jeweils Wasserstoff, Halogen, Trifluormethyl, Hydroxy, Alkyl mit 1-4 C-Atomen, Alkoxy mit 1-4 C-Atomen, Nitro, Cyano, Alkanoyl mit 2-4 C-Atomen bedeuten; Ar für Pyridyl, durch Halogen substituiertes Pyridyl oder Phenyl steht, das gegebenenfalls durch wenigstens einen Substituenten substituiert ist, der aus der Gruppe gewählt ist, die aus Halogen, Trifluormethyl, Hydroxy, Alkyl mit 1-4 C-Atomen, Alkoxy mit 1-4 C-Atomen, Amino, Alkanoylamino mit 2-4 C-Atomen, Nitro und Cyano besteht; und die durch eine strichlierte Linie angezeigte Bindungsstellung eine Einfach- oder eine Doppelbindung darstellt.
2. Die Verbindung nach Anspruch 1: 2-(4-Methoxyphenyl)-9-methyl-4,4a,5,6-tetrahydro- benzo[h]cinnolin-3(2H)-on.
3. Die Verbindung nach Anspruch 1: 9-Chloro-2-(4-methylphenyl)-4,4a,5,6-tetrahydrobenzo[h]cinnolin-3(2H)-on.
4. Die Verbindung nach Anspruch 1: 2-(4-Chlorphenyl)-9-fluoro-5,6-dihydrobenzo[h]cinnolin-3(2H)-on.
5. Die Verbindung nach Anspruch 1: 2-(4-Chlorphenyl)-9-fluoro-4,4a,5,6-tetrahydrobenzo[h]cinnolin-3(2H)-on.
6. Die Verbindung nach Anspruch 1: 9-Fluoro-2-phenyl-5,6-dihydrobenzo[h]cinnolin-3(2H)-on.
7. Die Verbindung nach Anspruch 1: 2-(4-Chlorphenyl)-9-methoxy-4,4a,5,6-tetrahydro- benzo[h]cinnolin-3(2H)-on.
8. Die Verbindung nach Anspruch 1: 9-Methoxy-2-(4-methoxyphenyl)-4,4a,5,6-tetrahydro- benzo[h]cinnolin-3(2H)-on..
9. Verfahren zur Herstellung einer Benzo[h]cinnolinverbindung der Formel
Figure imgb0015
worin X und Y die in Anspruch 1 angeführte Bedeutung besitzen, umfassend
(1) Umsetzen einer Verbindung der Formel
Figure imgb0016
worin R Wasserstoff oder Alkyl mit 1-4 C-Atomen darstellt und die übrigen Symbole die in Anspruch 1 angeführte Bedeutung besitzen, mit einer Verbindung der Formel
Figure imgb0017
 worin Ar die in Anspruch 1 angeführte Bedeutung besitzt, oder einem Säureadditionssaiz derselben, und darauffolgendes Unterwerfen der so erhaltenen Verbindung der Formel.
Figure imgb0018
worin jedes Symbol die in Anspruch 1 angeführte Bedeutung besitzt, einer Ringschlußreaktion, oder
(2) Zutropfen von Brom zu der Verbindung, worin die mit strichlierter Linie angegebene Bindungsstellung eine einfache Bindung ist, d.h. der Verbindung der Formel
Figure imgb0019
worin jedes der Symbole die in Anspruch 1 angeführte Bedeutung besitzt, oder Umsetzen der genannten Verbindung mit Natrium-m-nitrobenzolsulfonat, falls die mit strichlierter Linie angeführte Bindungsstellung der Verbindung eine Doppelbindung ist.
10. Pharmazeutische Zusammensetzung, die eine therapeutisch wirksame Menge der Verbindung nach Anspruch 1 und pharmazeutisch verträgliche Zusatzstoffe derselben enthält.
EP85904155A 1984-08-28 1985-08-26 Benzo-a,d,h-b,d-cinnolin-verbindungen, deren herstellung und arzneimittel die diese enthalten Expired - Lifetime EP0190367B1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AT85904155T ATE49595T1 (de) 1984-08-28 1985-08-26 Benzo-a,d,h-b,d-cinnolin-verbindungen, deren herstellung und arzneimittel die diese enthalten.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP59178789A JPH06763B2 (ja) 1984-08-28 1984-08-28 ベンゾ〔ｈ〕シンノリン誘導体
JP178789/84 1984-08-28

Publications (3)

Publication Number Publication Date
EP0190367A1 EP0190367A1 (de) 1986-08-13
EP0190367A4 EP0190367A4 (de) 1987-03-30
EP0190367B1 true EP0190367B1 (de) 1990-01-17

Family

ID=16054667

Family Applications (1)

Application Number Title Priority Date Filing Date
EP85904155A Expired - Lifetime EP0190367B1 (de) 1984-08-28 1985-08-26 Benzo-a,d,h-b,d-cinnolin-verbindungen, deren herstellung und arzneimittel die diese enthalten

Country Status (6)

Country Link
US (1) US4782057A (de)
EP (1) EP0190367B1 (de)
JP (1) JPH06763B2 (de)
DE (1) DE3575422D1 (de)
GB (1) GB2185977B (de)
WO (1) WO1986001506A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU578496B2 (en) * 1984-11-01 1988-10-27 Smith Kline & French Laboratories Limited Tricyclic heterocyclic compounds
JPH0633277B2 (ja) * 1986-01-10 1994-05-02 吉富製薬株式会社 ベンゾチオピラノ〔４，３−ｃ〕ピリダジン化合物
US4861773A (en) * 1986-04-28 1989-08-29 Smith Kline & French Laboratories Limited Heterocyclic compounds
ES2038708T3 (es) * 1987-03-02 1996-07-16 Yoshitomi Pharmaceutical Metodo para producir compuestos de benzotiepino(5,4-c)piridazina.
DE3887417T2 (de) * 1987-03-25 1994-05-26 Yoshitomi Pharmaceutical Thienocinnolinverbindungen und deren verwendung als heilmittel.
ATE92476T1 (de) * 1987-11-02 1993-08-15 Yoshitomi Pharmaceutical Kondensierte pyridazin-verbindungen und deren verwendung als arzneimittel.
JP2717687B2 (ja) * 1988-02-13 1998-02-18 日本曹達株式会社 ピリダジノン誘導体及びその製造方法
KR920007437B1 (ko) * 1988-09-21 1992-09-01 요시토미 세이야쿠 가부시기가이샤 티에노시클로 헵타 피리다진 화합물과 그것의 의약용도
CA2028496A1 (en) * 1989-10-31 1991-05-01 Tohru Nakao Thiophene compounds and their pharmaceutical uses
WO1993004069A1 (en) * 1991-08-27 1993-03-04 Yoshitomi Pharmaceutical Industries, Ltd. Fused pyridazine compound and pharmaceutical use thereof
US5597918A (en) * 1991-08-27 1997-01-28 Yoshitomi Pharmaceutical Industries, Ltd. Fused pyridazine compound
JP2800866B2 (ja) * 1992-01-30 1998-09-21 ソブエクレー商事 株式会社 活性水酸化マグネシウムの製造方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3464988A (en) * 1968-01-11 1969-09-02 Bristol Myers Co 3-hydrazinobenzo(h)cinnolines and 3 - hydrazinobenzocyclohepta-(5,6-c)pyridazines
JPS55118469A (en) * 1979-03-02 1980-09-11 Morishita Seiyaku Kk Thioamide derivative
US4602019A (en) * 1983-04-22 1986-07-22 Warner-Lambert Company Indeno[1,2-c]pyridazin-3-one derivatives useful as cardiotonic and antihypertensive agents
GB2164643B (en) * 1984-07-27 1988-11-02 Boehringer Biochemia Srl Tricyclic dihydropyridazinones and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
WO1986001506A1 (en) 1986-03-13
EP0190367A4 (de) 1987-03-30
JPS6156169A (ja) 1986-03-20
GB2185977B (en) 1990-01-17
GB2185977A (en) 1987-08-05
US4782057A (en) 1988-11-01
JPH06763B2 (ja) 1994-01-05
GB8602781D0 (en) 1986-03-12
DE3575422D1 (de) 1990-02-22
EP0190367A1 (de) 1986-08-13

Similar Documents

Publication Publication Date Title
EP0295656B1 (de) Benzthiazol-Derivate, ihre Anwendung und pharmazeutische Zusammensetzungen, die sie enthalten
EP0190367B1 (de) Benzo-a,d,h-b,d-cinnolin-verbindungen, deren herstellung und arzneimittel die diese enthalten
US4010279A (en) Biphenyloxy derivatives and antihyperlipidemic use
US4375479A (en) Indanyl derivatives and use
US4977152A (en) Novel tricyclic derivatives which are agonists of cholinergic receptors, and drugs in which they are present
HUT71132A (en) Bis-aryl-carbinol derivatives, pharmaceutical compositions containing them and process for producing
US4613599A (en) Method of treating thrombotic disease with pyridazinones
EP0030351A2 (de) Ergolin-Derivate, ihre Herstellung und sie enthaltende therapeutische Zusammensetzung
US4556739A (en) 3,4-Dialkoxy-2-alkylcarbonyl analino compounds
JP3466527B2 (ja) 新規なアコニチン系化合物および鎮痛・抗炎症剤
US4492699A (en) Triazolobenzodiazepine derivatives
PL114541B1 (en) Process for preparing novel,substituted in position 2,4a,9b-trans-5-aryl-2,3,4,4a,5,9b-hexahydro-1h-pyrido/4,3-b/indoles
KR930004675B1 (ko) 벤조[h] 신놀린 화합물의 제조방법
US4011323A (en) Bi-4-[1-(quinazolinyl-4)piperidyls] and bis{4-[1-(quinazolinyl-4)piperidyl]alkanes}
CA1054599A (fr) Derives de l'oxathiinno (1,4) (2,3-c) pyrrole' leur preparation et les compositions qui les contiennent
JPS6229585A (ja) エーテル化若しくはエステル化しうるジヒドロキシ基により位置２で置換された４―ｏｈキノリンカルボン酸の新規の誘導体、その製造方法、及び医薬としてのその使用
JPS61103874A (ja) アルキル置換ピリダジノン
US4454136A (en) Substituted benzopyranotriazoles and antiallergic use
US4085102A (en) 2-Amino-8-arylideno-3,4,5,6,7,8-hexahydro-4-arlypyrido[4,3-d]pyrimidines
US4980352A (en) Gem-dimethyl substituted bicyclic compounds useful as eukalemic diuretics
US4002617A (en) Hydrodipyrano-phthalazine compounds
EP0285267A3 (de) Pyridinderivate zur Behandlung oder Profilaxie von Leberschäden und Verfahren zu ihrer Herstellung
US5597918A (en) Fused pyridazine compound
CA1096385A (en) 5-(indol-3-ylmethylene)-1,3-dimethyl-2-methylimino-4- imidazolidinone
US4187312A (en) 3-Hydroxy-4,4-dimethyl-5-pyrrolidone derivatives

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19860423

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR IT LI NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19870330

17Q First examination report despatched

Effective date: 19880628

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE FR IT LI NL SE

REF Corresponds to:

Ref document number: 49595

Country of ref document: AT

Date of ref document: 19900215

Kind code of ref document: T

REF Corresponds to:

Ref document number: 3575422

Country of ref document: DE

Date of ref document: 19900222

ITF It: translation for a ep patent filed

Owner name: MODIANO & ASSOCIATI S.R.L.

ET Fr: translation filed
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
ITTA It: last paid annual fee
PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 19930727

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 19930730

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 19930802

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 19930805

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 19930826

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 19930831

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 19930914

Year of fee payment: 9

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Effective date: 19940826

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Effective date: 19940827

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Effective date: 19940831

Ref country code: CH

Effective date: 19940831

Ref country code: BE

Effective date: 19940831

EAL Se: european patent in force in sweden

Ref document number: 85904155.0

BERE Be: lapsed

Owner name: YOSHITOMI PHARMACEUTICAL INDUSTRIES LTD

Effective date: 19940831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Effective date: 19950301

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Effective date: 19950428

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Effective date: 19950503

EUG Se: european patent has lapsed

Ref document number: 85904155.0

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST